Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation
Crossref DOI link: https://doi.org/10.1007/s00277-017-3194-4
Published Online: 2017-11-30
Published Print: 2018-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kuykendall, Andrew T.
Shah, Savan
Talati, Chetasi
Al Ali, Najla
Sweet, Kendra
Padron, Eric
Sallman, David A.
Lancet, Jeffrey E.
List, Alan F.
Zuckerman, Kenneth S.
Komrokji, Rami S.
License valid from 2017-11-30